Azoximer bromide-modulated immune system (azoximer bromide adjuvant)

Azoximer bromide is a synthetic immunomodulatory adjuvant, commercially known as Polyoxidonium, widely used in Russia and some European countries. It is a water-soluble cationic polymer that enhances both innate and adaptive immunity when used as a vaccine adjuvant or in immunotherapy. Instead of targeting a single receptor or molecule, azoximer bromide acts through broad immunomodulation: activating innate immune cells (macrophages, neutrophils, natural killer cells), promoting dendritic cell maturation and antigen presentation, upregulating costimulatory molecules (e.g., ICOS ligand), and stimulating cytokine production. It can also induce transcriptional changes via the RIG-I/MDA5 signaling pathways and modulate NF-κB activity, contributing to its anti-infective, anti-inflammatory, and potential anti-tumor effects. Its mechanism includes the reduction of NETosis and enhancement of phagocytic and bactericidal functions. Azoximer bromide shows utility in infectious diseases, secondary immunodeficiencies, and cancer therapy as an immunotherapeutic adjuvant, with a strong safety and tolerability profile. This entry should not be considered a unique molecular “target” in the format of a receptor/enzyme but as a process or system-wide modulation by azoximer bromide. For structured databases, use “Azoximer bromide” as the agent and specify the affected immune components if possible.

Other names

Azoximer bromide-modulated immunityPolyoxidonium-modulated immunity (Polyoxidonium is the trade name of azoximer bromide)Azoximer bromide adjuvant effect

Enhances innate and adaptive immune responses Activates NF-κB pathway Modulates hydrogen peroxide concentrations within immune cells Induces expression of co-stimulatory molecules (e.g., ICOS ligand) Promotes transcription of cytosolic helicase MDA5 gene and possibly RIG-I pathway Increases phagocytic/bactericidal activity of macrophages and neutrophils